ARHGAP36 Inhibitors

ARHGAP36 inhibitors typically act by modulating the activity of GTPases and their associated pathways. Several inhibitors, such as Y-27632, H1152, GSK429286A, and RKI-1447, target the Rho/ROCK pathway. Given that ARHGAP36 is a RhoGAP, these inhibitors can indirectly reduce its functional activity by suppressing the Rho/ROCK pathway. The inhibition of this pathway decreases the number of active GTPases, thereby reducing the opportunity for ARHGAP36 to exert its GAP activity.

Other inhibitors, including NSC23766, ML141, EHT 1864, and ZCL278, target specific GTPases, such as Rac1 and Cdc42. These GTPases are known to interact with ARHGAP36, and their inhibition can reduce the pool of active GTPases with which ARHGAP36 can interact, leading to decreased ARHGAP36 function. Additional inhibitors, such as IPA-3, SecinH3, and ITX3, disrupt downstream signaling or manipulate the activities of other guanine nucleotide exchange factors (GEFs). IPA-3, for instance, inhibits PAK1, a downstream effector of Rho GTPases, thereby disrupting the signaling downstream of GTPase activation, which can indirectly lead to decreased ARHGAP36 functionality. SecinH3 and ITX3 inhibit Cytohesin and Trio, respectively, both of which are GEFs for various GTPases. By reducing the pool of active GTPases, these compounds can indirectly suppress the function of ARHGAP36. Tozasertib, on the other hand, inhibits Aurora A and B kinases, the inhibition of which can indirectly affect ARHGAP36 during cell division.